← Leaderboards
Ursula Buchholz
National Institute Of Allergy And Infectious Diseases
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Vaccine Candidate”
- Lawrence Corey · Fred Hutchinson Cancer Center$483,977,044
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$427,604,905
- Barton F Haynes · Duke University$290,267,445
- Kiran Datta · Leidos Biomedical Research, Inc.$277,585,346
- Peter B. Gilbert · Fred Hutchinson Cancer Center$195,104,733
- Wafaa M. El-Sadr · Columbia University Health Sciences$186,594,706
Research focus
Vaccine CandidateVaccinesAttenuatedReverse GeneticsProteinsVirusAttenuationImmunogenicityGenesPneumovirusPathogenClinical ResearchPara-Influenza Virus Type 3VectorViralInfantChildChildhoodInfectionParainfluenza VirusPreclinical StudyImmunogenicSerumEvaluation
Grant awards (30)
Laboratory And Pre-clinical Studies Of Parainfluenza Viruses$1,483,918
ZIA · FY2025 · AI · contact PI
Paramyxoviruses as Vaccine Vectors Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)$1,334,000
ZIA · FY2025 · AI · contact PI
Clinical Trials of Vaccines for Respiratory Syncytial Virus and Related Viruses$613,641
ZIA · FY2025 · AI · contact PI
Laboratory Studies of Human Respiratory Syncytial Virus and Other Pneumoviruses$613,641
ZIA · FY2025 · AI · contact PI
Paramyxoviruses as Vaccine Vectors Against Highly Pathogenic Viruses$106,721
ZIA · FY2025 · AI · contact PI
Laboratory And Pre-clinical Studies Of Parainfluenza Viruses$1,702,601
ZIA · FY2024 · AI · contact PI
Laboratory Studies of Human Respiratory Syncytial Virus and Other Pneumoviruses$1,306,400
ZIA · FY2024 · AI · contact PI
Clinical Trials of Vaccines for Respiratory Syncytial Virus and Related Viruses$1,306,400
ZIA · FY2024 · AI · contact PI
Paramyxoviruses as Vaccine Vectors Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)$496,575
ZIA · FY2024 · AI · contact PI
Paramyxoviruses as Vaccine Vectors Against Highly Pathogenic Viruses$227,201
ZIA · FY2024 · AI · contact PI
Paramyxoviruses as Vaccine Vectors Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)$2,955,452
ZIA · FY2023 · AI · contact PI
Laboratory And Pre-clinical Studies Of Parainfluenza Viruses$1,710,193
ZIA · FY2023 · AI · contact PI
Clinical Trials of Vaccines for Respiratory Syncytial Virus and Related Viruses$1,290,899
ZIA · FY2023 · AI · contact PI
Laboratory Studies of Human Respiratory Syncytial Virus and Other Pneumoviruses$1,290,899
ZIA · FY2023 · AI · contact PI
Paramyxoviruses as Vaccine Vectors Against Highly Pathogenic Viruses$107,577
ZIA · FY2023 · AI · contact PI
Laboratory And Pre-clinical Studies Of Parainfluenza Viruses$1,630,948
ZIA · FY2022 · AI · contact PI
Laboratory Studies of Human Respiratory Syncytial Virus and Other Pneumoviruses$1,356,084
ZIA · FY2022 · AI · contact PI
Clinical Trials of Vaccines for Respiratory Syncytial Virus and Related Viruses$887,620
ZIA · FY2022 · AI · contact PI
Paramyxoviruses as Vaccine Vectors Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)$321,289
ZIA · FY2022 · AI · contact PI
Paramyxoviruses as Vaccine Vectors Against Highly Pathogenic Viruses$221,905
ZIA · FY2022 · AI · contact PI
Laboratory And Pre-clinical Studies Of Parainfluenza Viruses$1,568,472
ZIA · FY2021 · AI · contact PI
Laboratory Studies of Human Respiratory Syncytial Virus and Other Pneumoviruses$1,123,296
ZIA · FY2021 · AI · contact PI
Clinical Trials of Vaccines for Respiratory Syncytial Virus and Related Viruses$1,051,597
ZIA · FY2021 · AI · contact PI
Paramyxoviruses as Vaccine Vectors Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)$698,609
ZIA · FY2021 · AI · contact PI
Paramyxoviruses as Vaccine Vectors Against Highly Pathogenic Viruses$215,100
ZIA · FY2021 · AI · contact PI
Laboratory And Pre-clinical Studies Of Parainfluenza Viruses$1,633,214
ZIA · FY2020 · AI · contact PI
Laboratory Studies of Human Respiratory Syncytial Virus and Other Pneumoviruses$1,258,386
ZIA · FY2020 · AI · contact PI
Clinical Trials of Vaccines for Respiratory Syncytial Virus and Related Viruses$1,258,384
ZIA · FY2020 · AI · contact PI
Paramyxoviruses as Vaccine Vectors Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)$787,601
ZIA · FY2020 · AI · contact PI
Paramyxoviruses as Vaccine Vectors Against Highly Pathogenic Viruses$279,642
ZIA · FY2020 · AI · contact PI